43 patents currently held
14 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Apr 2027. from the record
Of the 14 now held by other companies, 13 name Amicus Therapeutics Inc. as their current owner, and 1 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
23
Ending by 2030
Apr 2027
Next term end
21
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2028 · Low confidence
Also notable
Ends May 2038 · High confidence
Also notable
Ends May 2027 · Low confidence
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
US 10,925,866
Cited by 84 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2028. A terminal disclaimer caps this term to an earlier patent's.
Methods Of Treating Fabry Patients Having Renal Impairment
US 10,251,873
Cited by 48 later US patents, top 5% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2038.
Methods for Treatment of Fabry Disease
US 11,241,422
Cited by 53 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2027. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 4, 2027The maintenance fee for Method to Predict Response to Pharmacological Chaperone Treatment of Diseases (US 9,095,584) comes due Feb 4, 2027. Unpaid by Aug 4, 2027, it lapses early.
- 1 fee due Apr 15, 2027The maintenance fee for Arrays for Longitudinal Delivery of TTFields to a Body (US 10,441,776) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
- 2 fees due Jul 7 to 21, 2027 · next Jul 7
Recent changes
- 1 term has ended since Aug 20, 2026
What they patent
The 5 largest of its 21 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Assays for Diagnosing and Evaluating Treatment Options for Fabry Disease | 7 in force | to May 2027 |
| Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones | 4 in force | to Apr 2028 |
| Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene | 3 in force | to Mar 2037 |
| Drug Package | 3 in force | to Mar 2035 |
| Treating Cancer Using Electromagnetic Fields in Combination with Photodynamic Therapy | 3 in force | to Oct 2031 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,406,870 | Treating Cancer Using Electromagnetic Fields in Combination with Other Treatment Regimens In force · High confidence | In force | High confidence | |
| US 7,851,143 | Assays for Diagnosing and Evaluating Treatment Options for Fabry Disease In force · High confidence | In force | High confidence | |
| US 9,000,011 | Methods For Treatment of Fabry Disease In force · Medium confidence | In force | Medium confidence | |
| US 9,480,682 | Methods for Treatment of Fabry Disease In force · Low confidence | In force | Low confidence | |
| US 9,987,263 | Methods for Treatment of Fabry Disease In force · Low confidence | In force | Low confidence | |
| US 10,383,864 | Methods for Treatment of Fabry Disease In force · Low confidence | In force | Low confidence | |
| US 10,406,143 | Methods for Treatment of Fabry Disease In force (reinstated) · Low confidence | In force (reinstated) | Low confidence | |
| US 11,241,422 | Methods for Treatment of Fabry Disease In force · Low confidence | In force | Low confidence | |
| US 8,147,866 | Transmucosal Delivery Devices with Enhanced Uptake In force · High confidence | In force | High confidence | |
| US 9,655,843 | Transmucosal Delivery Devices with Enhanced Uptake In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 43: 14 patents in force now held by others · 32 patents ended · 1 application pending · 13 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.